{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"We calculated the number of patients who were alive without progression at 2 years","groups":[{"description":"* Nivolumab will be given every two weeks\n* The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle\n\nNivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.\n\nDC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.","id":"OG000","title":"Nivolumab+DC/Myeloma Fusions/GM-CSF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number of patients who were alive without progression at 2 years","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Patients Who Are Alive Without Progression at 2 Years","type":"SECONDARY","unitOfMeasure":"Participants"}